The debate over which form of stem cells will be most beneficial for clinical applications is far from over, and there may well never be a clear “winner.” The true winners will be the patients who will benefit from whichever method proves most feasible, cost effective, broadly accessible, and acceptable to regulatory agencies—whatever cell-based therapies can deliver the cures needed regardless of the source of the cells.
Recent Posts
- Do stem-cell transplants increase cancer risk? Long-lived recipients offer clues
- Re-engineered, blue light-activated immune cells penetrate and kill solid tumors
- Microenvironment-responsive nanomedicines: a promising direction for tissue regeneration
- Life Without Sickle Cell Beckons Boy Who Completed Gene Therapy
- Neuroscientists discover a mechanism that can reactivate dormant neural stem cells
- Human skin map gives ‘recipe’ to build skin and could help prevent scarring